About DaVita Venture Group
DaVita Venture Group is a venture capital firm founded in 2019. It is primarily based out of Denver, United States. As of Mar 2026, DaVita Venture Group is an active investor, having invested in 9 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from HealthTech to Enterprise Applications and Life Sciences. Most recently it participated in the $***** Series A round of R1 Therapeutics A lot of funds co-invest with DaVita Venture Group, with names like Abingworth sharing a substantial percentage of its portfolio. DaVita Venture Group has team of 8 people.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio Soonicorns
Deals in last 12 months
DaVita Venture Group's List of Top Investments
DaVita Venture Group has a portfolio of 9 companies. Their most notable investments are in Nephrosant and Xeltis.Their portfolio spans across United States and Switzerland. They have invested in HealthTech, Enterprise Applications, Life Sciences and 2 other sectors, across stages such as Series A, Series B and 2 more. Here is the list of top investments by DaVita Venture Group:
1. Wellth
Wellth provides an AI and cloud-based technology to healthcare payors and ACOs to produce cost-saving behavior changes in their members through science-based incentive plans. It engages and encourages customers to manage their diseases appropriately and take preventive actions. Users can log in to the platform and create a targeted incentive plan, set their goals, and allow verification of their results. Rewards are given to users who show positive change and maintain their health.
Key facts about Wellth
- Founded Year: 2014
- Location: Brooklyn (United States)
- Stage: Series C
- Total Funding till date: $73.1M
- Employee Count: 144 as on Jun 30, 2026
- Investors: New York Life Ventures, Tigerlabs and 34 Others
- Latest Funding Round: Series C, Aug 21, 2025, $*****
- Highlight: Editors' Pick
2. Heartbeat
Heartbeat provides a telemedicine platform for cardiology. The company offers a solution for providers and patients to connect for early diagnosis and management of heart disease. It also offers a telemedicine platform for employees. The company also offers its own app AI-based Heartbeat App for virtual consultation, meet online, share health information, and collaborate on treatment.
Key facts about Heartbeat
- Founded Year: 2017
- Location: New York City (United States)
- Stage: Series C
- Total Funding till date: $53.4M
- Employee Count: 129 as on Jun 30, 2026
- Investors: .406 Ventures, Optum Ventures and 10 Others
- Latest Funding Round: Series C, Jun 21, 2024, $*****
- Highlight: Editors' Pick
3. Xeltis
Developer of bioabsorbable synthetic heart valves and vascular grafts. The implants function as natural valves and vessels, allowing the body to heal. As the matrix gets absorbed over time, components of native tissue develop into functioning natural tissue. The flagship product is a replacement pulmonary valve for children with congenital heart malformations.
Key facts about Xeltis
- Founded Year: 2006
- Location: Zurich (Switzerland)
- Stage: Series D
- Total Funding till date: $176M
- Employee Count: 85 as on Jun 30, 2026
- Investors: Life Sciences Partners, EQT and 13 Others
- Latest Funding Round: Venture Debt, Dec 02, 2025, $*****
- Highlight: Editors' Pick
Key facts about Greater Good Health
- Founded Year: 2021
- Location: Los Angeles (United States)
- Stage: Series B
- Total Funding till date: $54.5M
- Employee Count: 111 as on Jun 30, 2026
- Investors: Allumia Ventures, Optum Ventures and 8 Others
- Latest Funding Round: Venture Debt, Mar 05, 2026, $*****
5. Dock Health
Provider of software for task management and collaboration platform. The platform is a secure hub for managing clinical tasks together. The platform provides a HIPAA-compliant collaborative solution to delegate & track what a team needs to deliver quality care for their patients. It comes with features for EHR integration, documentation, patient information management, and more.
Key facts about Dock Health
- Founded Year: 2017
- Location: Boston (United States)
- Stage: Series A
- Total Funding till date: $8M
- Employee Count: 15 as on Jun 30, 2026
- Investors: August Capital, MassMutual and 3 Others
- Latest Funding Round: Series A, May 12, 2023, $*****
- Highlight: Editors' Pick
DaVita Venture Group's Year-on-Year Investment Trends
DaVita Venture Group has invested in 9 companies over the last 6 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 1 investment, while as of Mar 2026, it has made 1 investment in this year. Its most recent first time investment was in R1 Therapeutics and most recent follow-on round was in Pathalys.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 1 | 0 | 1 |
2024 | 0 | 1 | 1 |
2023 | 3 | 0 | 3 |
2022 | 0 | 0 | 0 |
2021 | 2 | 0 | 2 |
2020 | 2 | 0 | 2 |
DaVita Venture Group's Investments by Stage
DaVita Venture Group has made 4 investments in Series A stage with an average round size of $27.1M, 3 investments in Series B stage with an average round size of $19.2M, 1 investment in Seed stage and 1 investment in Series D stage with an average round size of $34.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series B | 3 |
Seed | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
DaVita Venture Group's Investments by Sector
DaVita Venture Group has a diverse portfolio, with companies operating in the HealthTech, Enterprise Applications, Life Sciences, Vertical SaaS and Consumer. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 5 Software companies and at least 2 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
HealthTech | 5 |
Enterprise Applications | 3 |
Life Sciences | 3 |
Vertical SaaS | 2 |
Consumer | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
DaVita Venture Group's Investments by Geography
DaVita Venture Group has made most investments in United States (8), followed by Switzerland where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 8 |
Switzerland | 1 |
Note: We have considered here, only first round of investments
DaVita Venture Group's recent investments
DaVita Venture Group has made 1 investments in 2026 so far - R1 Therapeutics.Here are the most recent investments by DaVita Venture Group:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 17, 2026 | United States | Series A | 1693 | [+4] | |
Dec 17, 2025 | United States | Series B | 9614 | [+7] | |
Aug 20, 2024 | United States | Series B | 1236 | [+6] | |
May 12, 2023 | United States | Series A | 7750 | [+1] | |
Feb 21, 2023 | Switzerland | Series D | 2172 | [+2] |
Team profile of DaVita Venture Group
DaVita Venture Group has a team of 8 members including 1 Venture Partner and 5 Principals located in United States. DaVita Venture Group's team does not sit on the board of any company as of now.Here is a list of all team members in DaVita Venture Group:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Venture Partner | - | - | - | |
Principal | Denver | - | ||
Principal | - | - | - | |
Principal | - | - | - | |
Principal | - | - | - | |
Principal | - | - | - |
Co-investors of DaVita Venture Group
Over the past 6 years, 85 investors have co-invested in DaVita Venture Group's portfolio companies. This includes funds and angels.
- Invested before DaVita Venture Group: Optum Ventures, Yabeo and 42 others have invested in rounds before DaVita Venture Group. There are 2 companies where Optum Ventures has invested before DaVita Venture Group and 1 company where Yabeo has invested before DaVita Venture Group.
- Top Co-investors of DaVita Venture Group: 26 investors entered a company along with DaVita Venture Group. These include investors like Abingworth (2 companies).
- Invested after DaVita Venture Group: A total of 15 investors have invested in DaVita Venture Group's portfolio after their investments. Top Investors include SignalFire (1 company), Frank Williams (1 company) and Maycomb Capital (1 company).
Recent News related to DaVita Venture Group
•
Renal Disease Biotech R1 Therapeutics Nabs $77.5M for Phase 2bEndpoints•Mar 17, 2026•R1 Therapeutics, Alebund, Curie.Bio, DaVita Venture Group and 3 others
•
Greater Good Health Raises Series B to Improve Outcomes and Better Manage Medical SpendBusiness Wire•Mar 05, 2026•Allumia Ventures, HSBC Innovation Banking, Greater Good Health, DaVita Venture Group and 9 others
•
Pathalys secures $105m to advance SHPT drug through approvalPharmaceutical Technology•Aug 21, 2024•Pathalys, J P Morgan, Samsara BioCapital, Marshall Wace and 4 others
•
Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDAFierce Biotech•Aug 20, 2024•Pathalys, TCG Crossover, J.P. Morgan Asset Management, Samsara BioCapital and 6 others
•
Pathalys Pharma Raises $105M in Series B FundingFinSMEs•Aug 20, 2024•Pathalys, TCG Crossover, J.P. Morgan Asset Management, Samsara BioCapital and 5 others
•
Dutch medtech firm Xeltis secures €12.5M from EIC FundTech.eu•Aug 15, 2023•Xeltis, European Innovation Council, DaVita Venture Group, EQT and 5 others
•
•
•
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devicesGlobeNewswire•Feb 21, 2023•Xeltis, DaVita Venture Group, EQT, Invest-NL and 1 other
•
Pathalys Pharma brings in $150M for SHPT trialsLabiotech•Jan 19, 2023•Pathalys, Launch Therapeutics, The Carlyle Group, Abingworth and 4 others
